Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 20/20 | 0.71 |
| ▸ | AKT2 | P31751 | 16/20 | 0.71 |
| ▸ | AKT3 | Q9Y243 | 15/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.65 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30574756 | 0.91 | AKT1 (0.72) | AKT1AKT2AKT3CYP3A4CYP2D6 | |
| SCHEMBL25384538 | 0.91 | AKT1 (0.72) | AKT1AKT2AKT3CYP3A4CYP2D6 | |
| SCHEMBL30574917 | 0.91 | AKT1 (0.72) | AKT1AKT2AKT3CYP3A4CYP2D6 | |
| SCHEMBL25385020 | 0.91 | AKT1 (0.72) | AKT1AKT2AKT3CYP3A4CYP2D6 | |
| SCHEMBL31455005 | 0.90 | AKT1 (0.71) | AKT1AKT2AKT3CYP3A4CYP2D6 | |
| SCHEMBL30802360 | 0.90 | AKT1 (0.74) | AKT1AKT2AKT3CYP3A4CYP2D6 | |
| SCHEMBL31544824 | 0.88 | AKT1 (0.79) | AKT1AKT2AKT3CYP3A4CYP2D6 | |
| SCHEMBL26234267 | 0.88 | AKT1 (0.79) | AKT1AKT2AKT3CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL2174356 | 0.88 | AKT1 (0.75) | AKT1AKT2AKT3CYP3A4CYP2D6 | |
| SCHEMBL25385488 | 0.87 | AKT1 (0.77) | AKT1AKT2AKT3CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025059577-A1 | SUBSTITUTED AMINOPYRIDINE COMPOUNDS FOR USE AS AKT1 INHIBITORS | ATAVISTIK BIO, INC. (US) | 2025-03-20 | — | — | WO | disclosed |